Work

Rituximab leads to early elimination of circulating CD20+ T and B lymphocytes in patients with iTTP despite ongoing TPEx

Year: 2020

Type: article

Abstract: Key Points How TPEx impacts rituximab effectiveness in iTTP patients is not fully understood. In iTTP patients on therapeutic plasma exchange, rituximab eliminates circulating CD20+ B and T cells in 24 hours for at least 1 week.

Source: Blood Advances

DOI: 10.1182/bloodadvances.2019001148

Authors: Marcus A. Carden, Manila Gaddh, Abhinav Hoskote, Michael Brown, Virginia Merrill, Sean R. Stowell, Shanmuganathan Chandrakasan, Ana Antun, Ragini Kudchadkar, Sarah Kotanchiyev, David L. Jaye, Imre Bodó

Institutions: University of North Carolina at Chapel Hill, Emory University, Winship Cancer Institute, Children's Healthcare of Atlanta, Semmelweis University

Language: English

Topic: Complement system in diseases

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,800

Funders: Hungarian Scientific Research Fund, Nemzeti Kutatási Fejlesztési és Innovációs Hivatal, National Institutes of Health, National Heart, Lung, and Blood Institute, National Center for Advancing Translational Sciences

Awards: North Carolina Translational and Clinical Science Institute (NC TraCS) KL2, Examination of Initiating Factors that Regulate Red Blood Cell Alloimmunization

OpenAlex ID: W3004648324

FWCI: 0.525

Cites: 26

Cited by: 10

Related to: 10